Decision-Making in Bipolar Disorder
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- Change in Vigilance Assessed by the Melbourne Decision Making Questionnaire (MDMQ)
研究概览
简要总结
Forty subjects with bipolar disorder who are not receiving a mood-stabilizing medication for the treatment of their illness will participate in this study. The study aims to evaluate how decision-making is affected by treatment for bipolar disorder. Prior to beginning treatment, patients will complete questionnaires and a one-hour computer-administered assessment of decision-making. Differences between pre-post decision-making outcomes will be evaluated to examine whether the neuroeconomic concepts of risk aversion, loss aversion, risk tolerance and delay discounting are affected by treatment.
The overall goal of this study will be to identify whether decision-making in people with bipolar disorder is affected by treatment. Specifically the investigators will compare decision-making characteristics among bipolar patients prior to treatment with how these decision-making characteristics change over the course of 6 weeks of standard medication therapy for bipolar disorder. A total of 6 decision-making tasks and one control task will be administered via computer to eligible subjects. The investigators will evaluate decision-making under varying conditions of reward, risk, and uncertainty and over time. The investigators hypothesize that decision-making will improve across these assessments after 6 weeks of treatment.
详细描述
Participation in this study will require three study visits over 6 weeks. Subjects will be evaluated with the Structured Diagnostic Interview for DSM-IV to confirm diagnosis. They will also be administered the Hamilton Anxiety and Depression Rating Scales. Eligible subjects will then complete questionnaires related to their symptoms as well as decision-making and risk-taking, including: the Barratt Impulsiveness Scale, the Spielberger State-Trait Anxiety Inventory, and the Flinders Decision-making questionnaire. The Montgomery-Asburg Depression Severity scale to assess changes in depression symptom severity and the Young Mania Rating Scale to assess changes in manic symptom severity, will be conducted at screening, baseline, and endpoint. Patients will also be given the Childhood Trauma Questionnaire at baseline visit, to assess for a history of childhood trauma. The subjects will then complete the computer-generated decision-making tasks. Upon completion, the study physician will initiate standard-of-care treatment with a mood stabilizer (either lithium, valproate, or lamotrigine). Standard-of-care laboratory testing and psychiatric follow-up will be performed during the patient's study participation. After six weeks of treatment with a mood stabilizer, patients will again complete the decision-making computerized assessment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female, age 18-65
- •Primary DSM-IV TR Diagnosis of Bipolar Disorder, type I, II or NOS.
- •Ability to visually read and understand English language
- •Not currently taking any mood stabilizer or antipsychotic medication.
- •Women of reproductive potential must be willing to take a medically approved form of birth control throughout the duration of the study.
排除标准
- •Meet criteria for substance abuse or dependence within three months of the screening visit.
- •Presents with a clinically significant suicide risk, as assessed by a study physician.
- •Presence of any unstable or central nervous system-related medical illness that would interfere with cognition or participation.
- •Women who are currently pregnant or lactating, or plan to become pregnant during the study.
研究组 & 干预措施
Mood stabilizer
Participants diagnosed with Bipolar Disorder will receive standard of care open-label treatment with a mood stabilizer for six weeks.
干预措施: Lithium (Drug)
Mood stabilizer
Participants diagnosed with Bipolar Disorder will receive standard of care open-label treatment with a mood stabilizer for six weeks.
干预措施: Valproate (Drug)
Mood stabilizer
Participants diagnosed with Bipolar Disorder will receive standard of care open-label treatment with a mood stabilizer for six weeks.
干预措施: Lamotrigine (Drug)
结局指标
主要结局
Change in Vigilance Assessed by the Melbourne Decision Making Questionnaire (MDMQ)
时间窗: Baseline, Week 6
The MDMQ is a 22-item self report form assessing four different styles of decision making. Vigilance is considered the healthy, adaptive, decision-making style, reflecting consideration of an array of outcomes and ultimately rational decision-making. Scores range from 0-12. A higher score indicates that vigilance is used more frequently during decision making. A higher score indicates healthier decision making.
Change in Hypervigilance Assessed by the Melbourne Decision Making Questionnaire (MDMQ)
时间窗: Baseline, Week 6
The MDMQ is a 22-item self report form assessing four different styles of decision making. Hypervigilance is marked by hurried, anxious decision-making. Scores range from 0-10. A higher score indicates a "worse" score and that a hyper-vigilant decision making style is used more frequently.
Change in Buckpassing Assessed by the Melbourne Decision Making Questionnaire (MDMQ)
时间窗: Baseline, Week 6
The MDMQ is a 22-item self report form assessing four different styles of decision making. The buckpassing decision-making style represents a tendency to leave decisions to others. Scores range from 0-12. A higher score indicates that the buckpassing decision-making style is used more frequently and represents a "worse" score.
Change in Procrastination Assessed by the Melbourne Decision Making Questionnaire (MDMQ)
时间窗: Baseline, Week 6
The MDMQ is a 22-item self report form assessing four different styles of decision making. The procrastination decision-making style involves putting off making decisions. Scores range from 0-10. A higher score indicates that the procrastination decision-making style is used more and is considered a "worse" score.
次要结局
- Mean Difference in Barratt Impulsiveness Scale, Version 11 (BIS-11) Score(Baseline, Week 6)
研究者
Boadie W. Dunlop
Assistant Professor
Emory University